SOURCE: Lantis Laser Inc.

February 15, 2007 16:10 ET

Lantis' OCT Dental Imaging System™ to Participate in Growing Application of OCT Technology

DENVILLE, NJ -- (MARKET WIRE) -- February 15, 2007 -- Lantis Laser Inc. (PINKSHEETS: LLSR)

Lantis Laser Inc., under its worldwide exclusive rights for the dental field for Optical Coherence Tomography (OCT) technology, is developing its OCT Dental Imaging System™ for early detection of oral diseases.

OCT is a new class of diagnostic imaging technology that utilizes advanced photonics and fiber optics to obtain images never before possible. Operating similar to ultrasound, but using light instead of sound, OCT has an image resolution of 8-25 times greater than any other existing imaging modality.

This year, approximately 1,100,000 Americans will have a new or recurrent heart attack with up to 70 percent of these due to sudden rupture of unstable arterial plaques that cannot be detected using conventional imaging modalities. LightLab Imaging, the leader in this field, has developed a cardiovascular OCT system that captures images in the artery and has the potential to identify arterial plaque and more precisely direct conventional treatments for stable plaque -- angioplasty and stenting.

The application of OCT is most advanced in ophthalmology. Exclusive ophthalmology license holder, Carl Zeiss Meditec, recently announced the sale of their 6,000th Stratus OCT system, clearly indicating its acceptance in ophthalmology. At an approximate retail price of $65,000 this represents revenue of almost $400 million since its introduction in 2002.

OCT is also being researched in the field of cancer detection where it is ideally suited because of its ability to image at the cellular level. Most cancers begin as malformed cells and if caught early, may be curable. However, cells are too small to be imaged by existing medical imaging technologies. OCT is ideal for imaging in the gastrointestinal and in certain situations eliminates the need for biopsy due to its ultra-high resolution. Lantis intends participating in research on the early detection of oral cancers.

Forward-Looking Statements:

Certain statements in this press release, including statements regarding the anticipated development and expansion of Lantis' business, and the intent, belief or current expectations of Lantis, its directors or its officers, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

This press release is available at

Contact Information

  • Contact:
    Lantis Laser Inc.
    Stan Baron
    President and CEO
    Email Contact
    Tel. (203) 300-7622